About Chanzo Capital
Chanzo Capital is an Africa-focused venture firm with a thesis centered on backing the next generation of African technology entrepreneurs across fintech, commerce, agriculture, and adjacent sectors. The fund’s geographic footprint spans multiple African markets, with check sizes typical of African seed and pre-seed investing. Healthcare exposure is incidental rather than thematic, so founders should treat Chanzo as a generalist African early-stage investor whose interest in healthcare AI depends on the business model fit rather than a stated healthcare mandate. For healthcare AI founders, Chanzo is most relevant if you are an African-headquartered or Africa-deploying team at the pre-seed or seed stage, with check sizes plausibly $50K to $500K and a willingness to participate alongside other African seed investors. Stage focus is pre-seed and seed. Founders who should approach: African-based digital health, telemedicine, pharmacy, and supply-chain healthcare teams with a credible local commercial story; founders looking for an African co-investor to round out a syndicate. Founders who should not approach: US- or Europe-only companies, biotech, regulated medical devices, and any team without a credible African operating presence. Chanzo’s value-add tilts toward African operating networks, regulatory awareness in target markets, and downstream introductions to pan-African capital like Partech Africa, Ventures Platform, and Algebra Ventures. Entry path is warm introduction through African operators, portfolio CEOs, or co-investors in the regional seed ecosystem. Their LinkedIn page lists partners and provides direct contact. Be prepared to discuss country-specific regulatory pathways, unit economics that work at African price points, and the local team you have assembled.
Founder reviews
Pitch / review this investor
Have you raised from Chanzo Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).